-
公开(公告)号：US20240359184A1
公开(公告)日：2024-10-31
申请号：US18767337
申请日：2024-07-09
发明人： Hongshen MA , Samuel Guy BERRYMAN
IPC分类号： B01L3/00
CPC分类号： B01L3/5085 , B01L2300/0829 , B01L2300/0858 , B01L2300/12 , B01L2300/168
摘要： One aspect of the invention provides a well plate. The well plate may comprise a substrate, a primary structure attached to a first side of the substrate and a light absorbent secondary structure attached to the first side of the substrate. The primary structure may comprise a plurality of walls wherein the plurality of walls and the substrate together define a plurality of wells. The secondary structure may comprise, within each of the plurality of the wells, a plurality of sub-walls wherein each plurality of sub-walls and the substrate together define a plurality of sub-wells.
-
公开(公告)号：US12117354B2
公开(公告)日：2024-10-15
申请号：US17764725
申请日：2020-07-28
摘要： A pair of first electrodes 111, 112 is arranged in a state being separated in a direction parallel to a contact surface 102 of a base material 10 made of a dielectric and being at least partially in contact with the base material 10. A pair of second electrodes 121, 122 is arranged in a state of overlapping at least one of the pair of first electrodes and sandwiching the base material 10 at a position farther from the contact surface 102 of the base material 10 than the pair of first electrodes 111 and 112 in a direction perpendicular to the contact surface 102 of the base material 10. The proximity state of an object Q with respect to the contact surface 102 of the base material 10 is detected according to the measurement result of the capacitance C1 between the pair of first electrodes 111 and 112.
-
公开(公告)号：US12109179B2
公开(公告)日：2024-10-08
申请号：US17599329
申请日：2020-03-27
发明人： Peter Virsik , Han-Jie Zhou , Marianne Dorothy Sadar , Raymond John Andersen , Kunzhong Jian , Daniel Andrew Golec
IPC分类号： A61K31/145 , A61K31/203 , A61K31/519
CPC分类号： A61K31/145 , A61K31/203 , A61K31/519
摘要： The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.
-
公开(公告)号：US12084360B2
公开(公告)日：2024-09-10
申请号：US18111490
申请日：2023-02-17
发明人： Fariborz Taghipour
IPC分类号： C02F1/32 , C02F1/72 , C02F103/02
CPC分类号： C02F1/325 , C02F1/725 , C02F1/32 , C02F2103/026 , C02F2201/3222 , C02F2201/3228 , C02F2307/10 , C02F2307/12
摘要： A reactor that operates with ultraviolet light emitting diodes (UV-LEDs) to attain UV photoreactions or UV photo-initiated reaction in a fluid flow for various applications, including water purification. The UV-LED reactor is comprised of a conduit means for passing fluid flow, an ultraviolet light emitting diode (UV-LED), and a radiation-focusing element to focus the UV-LED radiation to the fluid in the longitudinal direction of the conduit. The UV-LED reactor may include photocatalysts or chemical oxidants, which are activated by UV emitted by UV-LEDs for photocatalytic and photo-initiated reactions.
-
公开(公告)号：US12053524B2
公开(公告)日：2024-08-06
申请号：US17402460
申请日：2021-08-13
发明人： Kelley Marshall McNagny , Calvin D. Roskelley , Michael R. Hughes , Diana Canals Hernaez , Klas Ola Blixt , John Stephen Babcook , Christopher John Bond , Ismael Samudio , Jan Peter Bergqvist , Katherine Grace MacDonald , Anna Von Rossum , Bradley John Hedberg , Pamela Megan Dean
IPC分类号： A61K39/00 , A61K35/17 , A61K39/395 , A61K47/68 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/28 , C07K16/30 , C12N5/10
CPC分类号： A61K39/39558 , A61K35/17 , A61K47/6803 , A61K47/6809 , A61K47/6817 , A61K47/6849 , A61K47/6851 , A61P35/00 , C07K14/705 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K16/28 , C07K16/30 , C07K16/3076 , C12N5/10 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K2317/24 , C07K2317/33 , C07K2317/622 , C07K2317/732 , C07K2317/92 , C07K2319/03 , C07K2319/33 , C07K2319/41
摘要： The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer.
-
公开(公告)号：US20240243649A1
公开(公告)日：2024-07-18
申请号：US18416877
申请日：2024-01-18
发明人： Xiaodong LU , Irfan-Ur-Rab USMAN
CPC分类号： H02K41/02 , H01L21/67 , H02K1/26 , H02K1/2795 , H02K3/28 , H02K7/09 , H02K21/24 , H02K41/031 , H02K2201/18
摘要： Displacement devices comprise a stator and a moveable stage. The stator comprises a plurality of coils shaped to provide pluralities of generally linearly elongated coil traces in one or more layers. Layers of coils may overlap in the Z-direction. The moveable stage comprises a plurality of magnet arrays. Each magnet array may comprise a plurality of magnetization segments generally linearly elongated in a corresponding direction. Each magnetization segment has a magnetization direction generally orthogonal to the direction in which it is elongated and at least two of the magnetization directions are different from one another. One or more amplifiers may be connected to selectively drive current in the coil traces and to thereby effect relative movement between the stator and the moveable stage.
-
7.发明公开公开(公告)号：US20240240149A1
公开(公告)日：2024-07-18
申请号：US18561873
申请日：2022-05-18
IPC分类号： C12N5/0789
CPC分类号： C12N5/0647 , C12N2500/24 , C12N2500/38 , C12N2500/44 , C12N2501/105 , C12N2501/115 , C12N2501/125 , C12N2501/155 , C12N2501/165 , C12N2501/2303 , C12N2501/2306 , C12N2501/2311 , C12N2501/26 , C12N2501/42 , C12N2501/585 , C12N2506/28 , C12N2513/00
摘要： Described herein is a method for producing blood progenitor (hematopoietic progenitor cells) and T cell progenitor cells and to cells produced or obtainable by the process and the use of said cells, the method including: (a) optionally subjecting pluripotent stem cells under conditions that direct the cells to become mesoderm and subsequently hemogenic endothelial cells; and (b) directing hemogenic endothelial cells to differentiate into blood progenitor cells, preferably defined blood progenitor cells) using a media formulation designed to promote endothelial to hematopoietic transition (EHT) while being cultured on a surface functionalised with ligands designed to activate the Notch signaling pathway. In some aspects the ligands are Notch ligands, such as DLL4 and integrin ligands, such as integrin α4β1 ligand or VCAM1.
-
公开(公告)号：US20240216610A1
公开(公告)日：2024-07-04
申请号：US18541187
申请日：2023-12-15
发明人： Guy Dumont , Mark Ansermino , Sara Khosravi , Nicholas West
CPC分类号： A61M5/1723 , A61B5/00 , A61B5/369 , A61B5/4821 , A61B5/4839 , A61B5/725 , A61M5/172 , G16H20/13 , A61M5/14 , A61M2005/14296 , A61M2202/048 , A61M2205/3303 , A61M2205/50 , A61M2230/06 , A61M2230/10 , A61M2230/30 , A61M2230/42 , A61M2230/43
摘要： A control system for administration of a drug comprises a drug administration actuator for administering the drug to a patient at a controllable dosage; a monitor for measuring an effect of the drug on the patient; and a controller configured to determine a control signal to the drug administration actuator; wherein the controller is configured to implement a closed loop model-predictive control scheme comprising, for each of a series of time steps, minimizing a cost function subject to one or more constraints to determine the control signal, the cost function based at least in part on a reference level and the monitor measurement; wherein the control signal is used as an input to an auxiliary model to estimate at least one concentration level of the drug in the patient; and wherein the constraints comprise at least one constraint on the estimate of the concentration level of the drug.
-
公开(公告)号：US20240181062A1
公开(公告)日：2024-06-06
申请号：US18551390
申请日：2022-03-21
申请人： New York University , The University of British Columbia , Ludwig-Maximilians-Universität München
发明人： Dirk TRAUNER , Johannes MORSTEIN , Pieter Rutter CULLIS , Dominik WITZIGMANN , Nisha CHANDER , David B. KONRAD
IPC分类号： A61K41/00 , A61K9/127 , A61K31/704 , C07F9/10
CPC分类号： A61K41/0042 , A61K9/1271 , A61K31/704 , C07F9/106
摘要： Provided are photoswitchable glycerophospholipids having a photoswitchable group having the following structure: or The photoswitchable glycerophospholipids can be isomerized by red spectral light. Also disclosed are nanovesicles (e.g., liposomes). Also disclosed are methods of making the photoswitchable glycerophospholipids and nanovesicles formed therefrom. The present disclosure further provides methods of using the nanovesicles. e.g., for targeted delivery of cargo. A photoswitchable glycerophospholipid may have the following structure: Structure I.
-
10.发明公开公开(公告)号：US20240109771A1
公开(公告)日：2024-04-04
申请号：US18476229
申请日：2023-09-27
CPC分类号： B81C1/00293 , B81B3/0021 , B81B2203/0127 , B81C2203/0172
摘要： A method for fabricating a micro-fabricated device comprising a cavity-defining surface which defines a cavity, comprises: fabricating a channel that provides fluid communication with the cavity, the channel comprising a Tesla valve for permitting fluid flow in a first direction out of the cavity and through the channel while impeding fluid flow through the channel into the cavity in a second direction opposed to the first direction; and applying a sealing material to the device to thereby seal the channel, wherein applying the sealing material comprises: introducing the sealing material to the channel; and depositing the sealing material onto one or more channel-defining surfaces. The sealing material is prevented from reaching the cavity at least in part by the action of the Tesla valve.
-
-
-
-
-
-
-
-
-
搜索结果
1221 条记录 (耗时 0.038 秒)
